The objectives of this project are to define the mechanisms of autoimmunity in MRL/lpr mice, an animal model of systemic lupus-like autoimmune disease, and to develop approaches for controlling autoimmunity in vivo. The underlying hypothesis is that lpr lymphocytes are resistant to tolerance (anergy or deletion)-inducing stimuli, leading to abnormal development of T cells and excessive cytokine production, and anomalous response patterns of B cells. In addition, these abnormalities may be associated with aberrant expression of surface molecules that are involved in lymphocyte interactions and that may serve as targets for specific antagonists. The following specific aims are proposed: 1. Immunohistologic analysis of lymphocyte development and activation: In order to define cellular abnormalities in vivo, immunohistochemistry will be used to examine cytokine-producing T cells in lymphoid tissues of lpr and control mice, their kinetics of appearance, and their relation to activated autoantibody-producing B cells. The lifespans of lymphocytes in lpr mice, and in lpr x normal chimeras, will be studied by in vivo BUDR labeling. 2. Role of cytokines in autoantibody production: Antagonists against defined cytokines (IL4, IFNgamma) will be administered to lpr mice, and effects on autoantibody titers, immune complex-mediated lesions and lymphoproliferation will be examined. To complement this approach, lpr and +/+ mice will be mated with IL4 transgenic mice, to examine the effects of IL4 over-expression on autoimmunity. 3. Anergy in lpr-derived lymphocytes: The susceptibility of lpr-derived resting T cells and neonatal B lymphocytes to tolerance will be examined. A class II-restricted cytochrome c-specific TCR transgene will be bred into lpr mice, and effects on autoimmunity as well as tolerance in these homogeneous T cells will be examined. 4. Lymphocyte surface markers in lpr mice: the expression of three surface proteins, B7, CD22 and CD40, that are known to be involved in T-B cell interactions, will be studied in resting and activated lpr lymphocytes of different ages. Attempts will be made to produce monoclonal antibodies specific for lpr B cells. the ability of antibodies or inhibitors against these surface proteins to block autoimmunity will be examined.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
1R01AI032531-01A1
Application #
3147651
Study Section
Immunological Sciences Study Section (IMS)
Project Start
1993-01-01
Project End
1995-12-31
Budget Start
1993-01-01
Budget End
1993-12-31
Support Year
1
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02115
Wang, J K; Ju, S T; Marshak-Rothstein, A (2000) Protection of T cells from activation-induced cell death by Fas+ B cells. Eur J Immunol 30:931-7
Gochuico, B R; Zhang, J; Ma, B Y et al. (2000) TRAIL expression in vascular smooth muscle. Am J Physiol Lung Cell Mol Physiol 278:L1045-50
Xiao, S; Matsui, K; Fine, A et al. (1999) FasL promoter activation by IL-2 through SP1 and NFAT but not Egr-2 and Egr-3. Eur J Immunol 29:3456-65
Van Parijs, L; Biuckians, A; Abbas, A K (1998) Functional roles of Fas and Bcl-2-regulated apoptosis of T lymphocytes. J Immunol 160:2065-71
Van Parijs, L; Peterson, D A; Abbas, A K (1998) The Fas/Fas ligand pathway and Bcl-2 regulate T cell responses to model self and foreign antigens. Immunity 8:265-74
Refaeli, Y; Van Parijs, L; London, C A et al. (1998) Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity 8:615-23
Rifkin, I R; Channavajhala, P L; Kiefer, H L et al. (1998) Acceleration of lpr lymphoproliferative and autoimmune disease by transgenic protein kinase CK2 alpha. J Immunol 161:5164-70
Matsui, K; Fine, A; Zhu, B et al. (1998) Identification of two NF-kappa B sites in mouse CD95 ligand (Fas ligand) promoter: functional analysis in T cell hybridoma. J Immunol 161:3469-73
Van Parijs, L; Biuckians, A; Ibragimov, A et al. (1997) Functional responses and apoptosis of CD25 (IL-2R alpha)-deficient T cells expressing a transgenic antigen receptor. J Immunol 158:3738-45
Wang, J K; Zhu, B; Ju, S T et al. (1997) CD4+ T cells reactivated with superantigen are both more sensitive to FasL-mediated killing and express a higher level of FasL. Cell Immunol 179:153-64

Showing the most recent 10 out of 19 publications